PMID- 16142359
OWN - NLM
STAT- MEDLINE
DCOM- 20060203
LR  - 20171116
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 14
IP  - 4
DP  - 2005 Oct
TI  - Administration of dendritic cells in cancer nodules in hepatocellular carcinoma.
PG  - 969-73
AB  - Dendritic cells (DCs), the most potent antigen-presenting cells in vivo, are now 
      used for cancer immunotherapy during which they are usually administered to the 
      blood of patients with cancer. However, the route of administration of DCs 
      affects the magnitude of immune responses. This study was conducted to assess the 
      safety of the direct administration of DCs into cancer nodules. DCs were 
      generated by culturing peripheral blood mononuclear cells with 
      granulocyte-macrophage colony-stimulating factor and interleukin-4 for 7 days. 
      After confirming the phenotype and function, one hundred thousand DCs were 
      injected directly into the cancer nodules of 4 patients with hepatocellular 
      carcinoma (HCC) under ultrasonography guidance 48 h after the administration of 
      100% ethanol. All patients were monitored for any alteration in generalized 
      condition, signs of inflammation, and liver and kidney function for the next 14 
      days. In addition, the final assessment of the safety of the administration of 
      DCs into cancer nodules was performed 6 months after therapy commencement. The 
      injection of 100% ethanol disrupted the HCC nodules in all 4 patients. DCs were 
      distributed uniformly in the cancer nodules as assessed by ultrasonography. The 
      administration of DCs into cancer nodules was well tolerated by all patients and 
      there were no immediate or delayed side effects. The tumor marker decreased in 
      one patient after the direct administration of DCs. Direct administration of DCs 
      into the cancer nodules of patients with HCC was safe.
FAU - Kumagi, Teru
AU  - Kumagi T
AD  - Third Department of Internal Medicine, Ehime University School of Medicine, To-on 
      city, Ehime 791-0295, Japan.
FAU - Akbar, S M Fazle
AU  - Akbar SM
FAU - Horiike, Norio
AU  - Horiike N
FAU - Kurose, Kiyotaka
AU  - Kurose K
FAU - Hirooka, Masashi
AU  - Hirooka M
FAU - Hiraoka, Atsushi
AU  - Hiraoka A
FAU - Hiasa, Yoichi
AU  - Hiasa Y
FAU - Michitaka, Kojiro
AU  - Michitaka K
FAU - Onji, Morikazu
AU  - Onji M
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (B7-2 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-DR Antigens)
RN  - 207137-56-2 (Interleukin-4)
RN  - 3K9958V90M (Ethanol)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Aged
MH  - Antigen Presentation
MH  - B7-2 Antigen/biosynthesis
MH  - Biomarkers, Tumor
MH  - Cancer Vaccines
MH  - Carcinoma, Hepatocellular/*pathology/*therapy
MH  - Dendritic Cells/*cytology/*pathology
MH  - Ethanol/pharmacology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/metabolism
MH  - HLA-DR Antigens/metabolism
MH  - Humans
MH  - Immunotherapy/methods
MH  - Immunotherapy, Adoptive/methods
MH  - Inflammation
MH  - Interleukin-4/metabolism
MH  - Leukocytes, Mononuclear/cytology/metabolism
MH  - Liver/pathology
MH  - Liver Neoplasms/*pathology/*therapy
MH  - Male
MH  - Phenotype
MH  - Pilot Projects
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Ultrasonography
EDAT- 2005/09/06 09:00
MHDA- 2006/02/04 09:00
CRDT- 2005/09/06 09:00
PHST- 2005/09/06 09:00 [pubmed]
PHST- 2006/02/04 09:00 [medline]
PHST- 2005/09/06 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2005 Oct;14(4):969-73.